Endocan as a biomarker of endothelial dysfunction in cancer

Journal of Cancer Science and Therapy

Volumn 2, Issue 2, 2010, Pages 47-52

  Stéphane, Sarrazin ^a   Claude Alain, Maurage ^b   Dominique, Delmas ^c   Philippe, Lassalle ^d   Maryse, Delehedde ^d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Futurs Health Products   (France)

^d UNIV LILLE   (France)

^e INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Angiogenesis; Biomarker; Diagnosis; Endocan; Endothelial dysfunction; ESM 1; Personalized medicine; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CELL PROTEIN; ENDOTHELIAL CELL SPECIFIC MOLECULE 1; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

BRAIN BLOOD VESSEL; BRAIN TUMOR; CANCER SURVIVAL; DISEASE MARKER; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HEALTH CARE COST; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KIDNEY BLOOD VESSEL; KIDNEY TUMOR; LUNG BLOOD VESSEL; LUNG TUMOR; NEOPLASM; NONHUMAN; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW;

EID: 77954673577     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000022     Document Type: Review

References (48)

1. Abid MR, Yi X, Yano K, Shih SC, Aird WC (2006) Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res 72: 136-145.
2. Aird WC (2007) Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 100: 158-173.
3. Aitkenhead M, Wang SJ, Nakatsu MN, Mestas J, Heard C, et al. (2002) Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: induction of ESM-1, (beta)ig-h3, and NrCAM. Microvasc Res 63: 159-171.
4. Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, et al. (2009) Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 69: 836-844.
5. Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, et al. (2004) Tissuewide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 64: 844-856.
6. Bechard D, Gentina T, Delehedde M, Scherpereel A, Lyon M, et al. (2001a) Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem 276: 48341-48349.
7. Bechard D, Meignin V, Scherpereel A, Oudin S, Kervoaze G, et al. (2000) Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 37: 417-425.
8. Bechard D, Scherpereel A, Hammad H, Gentina T, Tsicopoulos A, et al. (2001b) Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/ CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 167: 3099-3106.
9. Bergers G, Hanahan D (2008) Modes of resistance to antiangiogenic therapy. Nature Rev Cancer 8: 592-603.
10. Bertolini F, Mancuso P, Shaked Y, Kerbel RS (2007) Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Today 12: 806-812.
11. Borczuk AC, Shah L, Pearson GD, Walter KL, Wang L, et al. (2004) Molecular signatures in biopsy specimens of lung cancer. Am J Respir Crit Care Med 170: 167-174.
12. Buckanovich RJ, Sasaroli D, O'Brien-Jenkins A, Botbyl J, Hammond R, et al. (2007) Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 25: 852-861.
13. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438: 932-936.
14. Cifola I, Spinelli R, Beltrame L, Peano C, Fasoli E, et al. (2008) Genome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profile. Mol Cancer 7: 6.
15. De Freitas Caires N, Barrier M, Sarrazin S, Depontieu F, Ghamlouch H, et al. (2009) Identification of cathepsin G in the generation of elastase-resistant fragment of vascular endocan: involvement in the regulation of LFA-1-dependent cascade. Critical Care 13: P16.
16. Delehedde M, Sarrazin S, Adam E, Motte V, Vanpouille C (2006) Proteoglycans and glycosaminoglycans: Complex molecules with modulating activity. In: Delehedde & Lortat-Jacob, Eds. New Developments in Therapeutic Glycomics. Kerala: Research Signpost, pp 1-13.
17. Depontieu F, Grigoriu BD, Scherpereel A, Adam E, Delehedde M, Gosset P, et al. (2008) Loss of Endocan tumorigenic properties after alternative splicing of exon 2. BMC Cancer 8: 14.
18. Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparinbinding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161: 851-858.
19. Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, et al. (1990) Expression of the CD34 gene in vascular endothelial cells. Blood 75: 2417-2426.
20. Fiedler U, Christian S, Koidl S, Kerjaschki D, Emmett MS, et al. (2006) The Sialomucin CD34 Is a Marker of Lymphatic Endothelial Cells in Human Tumors Am J Pathol 168: 1045-1053.
21. Folkman J, Klagsbrun M (1987) Angiogenic factors. Science 235: 442-447.
22. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
23. Folkman J (2006) Angiogenesis. Annu Rev Med 57: 1-18.
24. Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, et al. (2006) Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 12: 4575-4582.
25. Hardwick JS, Yang Y, Zhang C, Shi B, McFall R, et al. (2005) Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling. Mol Cancer Ther 4: 413-425.
26. Hatfield K, Oyan AM, Ersvaer E, Kalland KH, Lassalle P, et al. (2009) Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. Br J Haematol 144: 53-68.
27. Huang GW, Tao YM, Ding X (2009) Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci 54: 389-394.
28. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358: 2039-2049.
29. Lacroix L, Lazar V, Michiels S, Ripoche H, Dessen P, et al. (2005) Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations. Am J Pathol 167: 223-231.
30. Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, et al. (1996) ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 271: 20458-20464.
31. Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT, et al. (2003) Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer 3: 31.
32. Leroy X, Aubert S, Zini L, Franquet H, Kervoaze G, et al. (2010) Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology 56: 180-187.
33. Maurage CA, Adam E, Mineo JF, Sarrazin S, Debunne M, et al. (2009) Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol 68: 633-641.
34. Perey L, Benhattar J, Peters R, Jaunin P, Leyvraz S (2001) High tumour contamination of leukaphereses in patients with small cell carcinoma of the lung: a comparison of immunocytochemistry and RT-PCR. Br J Cancer 85: 1713-1721.
35. Plouet J, Schilling J, Gospodarowicz D (1989) Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells. EMBO J 8: 3801-3808.
36. Recchia FM, Xu L, Penn JS, Boone B, Dexheimer PJ (2010) Identification of genes and pathways involved in retinal neovascularization by microarray analysis of two animal models of retinal angiogenesis. Invest Ophthalmol Vis Sci 51: 1098-1105.
37. Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, et al. (2007) Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res 313: 1285-1294.
38. Ryningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT, et al. (2009) A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leuk Res 33: 779-787.
39. Ryningen A, Stapnes C, Paulsen K, Lassalle P, Gjertsen BT, et al. (2008) In vivo biological effects of ATRA in the treatment of AML. Expert Opin Investig Drugs 17: 1623-1633.
40. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, et al. (2006) Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 1765: 25-37.
41. Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, et al. (2006) Endocan, a new endothelial marker in human sepsis. Crit Care Med 34: 532-537.
42. Scherpereel A, Gentina T, Grigoriu B, Senechal S, Janin A, et al. (2003) Overexpression of endocan induces tumor formation. Cancer Res 63: 6084-6089.
43. Shin JW, Huggenberger R, Detmar M (2008) Transcriptional profiling of VEGFA and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis. Blood 112: 2318-2326.
44. Strasser GA, Kaminker JS, Tessier-Lavigne M (2010) Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching. Blood (Epub ahead of print).
45. Tissier S, Lancel S, Marechal X, Mordon S, Depontieu F, et al. (2004) Calpain inhibitors improve myocardial dysfunction and inflammation induced by endotoxin in rats. Shock 21: 352-357.
46. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
47. Wattel S, Mircescu H, Venet D, Burniat A, Franc B, et al. (2005) Gene expression in thyroid autonomous adenomas provides insight into their physiopathology. Oncogene 24: 6902-6916.
48. Zuo L, Zhang SM, Hu RL, Zhu HQ, Zhou Q, et al. (2008) Correlation between expression and differentiation of endocan in colorectal cancer. World J Gastroenterol 14: 4562-4568.